Cholinergic receptor genes exhibited varying levels of expression across malignant cells within DMG tumors (Figure S9A), reflecting intratumoral heterogeneity—a phenomenon well-described in this disease11 and in gliomas in general.46–48 Pseudo-bulk expression in malignant cells revealed that the muscarinic receptor CHRM3 was highly expressed across all glioma subtypes, as well as in ependymoma and medulloblastoma (Figure S9B). This evidence concerns the gene CHRM3 and central nervous system cancer.